| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 03.03.2016 og
angivet som gældende fra 01.03.2016 (3078
dage). |
Ingen historik.
| Branche | | Fremstilling af farmaceutiske præparater (212000). |
| Sidst opdateret den 03.05.2016 og
angivet som gældende fra 28.04.2016 (3020
dage). |
| Historik | Start | Stop |
|---|
| Fremstilling af farmaceutiske præparater (212000) | 28.04.2016 | |
| Uoplyst (999999) | 01.03.2016 | 27.04.2016 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 29.04.2016 og
angivet som gældende fra 28.04.2016 (3020
dage). |
| Historik | Start | Stop |
|---|
| false | 28.04.2016 | |
| true | 01.03.2016 | 27.04.2016 |
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | AKI Therapeutics A/S. |
| Sidst opdateret den 14.06.2022 og
angivet som gældende fra 31.05.2022 (796
dage). |
| Historik | Start | Stop |
|---|
| AKI Therapeutics A/S | 31.05.2022 | |
| AKI Therapeutics ApS | 13.09.2019 | 30.05.2022 |
| Renoguard ApS | 28.04.2016 | 12.09.2019 |
| ApS STM nr. 4310 | 01.03.2016 | 27.04.2016 |
| Tegningsregel | | Selskabet tegnes af en direktør og formanden for bestyrelsen i forening eller af den samlede bestyrelse. |
| Sidst opdateret den 06.07.2021 og
angivet som gældende fra 06.07.2021 (1125
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | 1 direktør + formanden |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af en direktør og formanden for bestyrelsen i forening eller af den samlede bestyrelse | 06.07.2021 | |
| Selskabet tegnes af en direktør | 01.03.2016 | 05.07.2021 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Grant Thornton Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:34209936
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the section “Auditor’s responsibilities for the audit of the financial statements”. We are independent of the company in accordance with International Ethical requirements for auditors (IESBA’s Code of Ethics), and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):OpinionWe have audited the financial statements of AKI Therapeutics A/S for the financial year January 1 – December 31, 2023, which comprise statement of comprehensive income, statement of financial position, statement of changes in equity, statement of cash flows, accounting policies and notes. The financial statements are prepared in accordance with International Reporting Standards as endorsed by the EU and further requirements in the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the company at December 31, 2023 and of the results of the company's operations and cash flows for the financial year January 1 – December 31, 2023 in accordance with International Reporting Standards as issued by the International Accounting Standards Board (IASB) and adopted by the EU and additional requirements of the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the management's reviewThe management is responsible for the management's Review. Our opinion on the financial statements døs not cover the management’s Review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management´s Review and in doing so, consider whether Management´s Review is materially inconsistent with the financial statements or knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management´s Review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that Management´s Review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of Management´s Review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration